Peer Reviewed Publications

Reviews

  1. Membrane Transporters in Physiological Barriers of Pharmacological Importance
  2. Nagy I, Toth B, Gaborik Z, Erdo F, Krajcsi P. CURR PHARM DES. 2016. doi: 10.2174/1381612822666160726101748. PubMed PMID: 27464727.
  3. Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
  4. Safar Z, Vasko B, Ritchie TK, Imre G, Mogyorosi K, Erdo F, Rajnai Z, Fekete Z, Szeremy P, Muka L, Zolnerciks JK, Heredi-Szabo K, Ragueneau-Majlessi I, Krajcsi P. CURR DRUG METAB. 2016 17(5):430-55. doi: 10.2174/1389200217666160105111304. PubMed PMID: 26728264.
  5. Pre-Plated Cell Lines for ADMETox Applications in the Pharmaceutical Industry
  6. Torres FM, Safar Z, Vazquez-Sanchez MA, Kurunczi A, Kis E, Magnan R, Jani M, Nicolas JO, Krajcsi P. CURR PROTOC TOXICOL. 2015 65:23 8 1-. doi: 10.1002/0471140856.tx2308s65. PubMed PMID: 26250397.
  7. Mechanisms and therapeutic potential of inhibiting drug efflux transporters
  8. Klukovits A, Krajcsi P. EXPERT OPIN DRUG METAB TOXICOL. 2015 11(6):907-20. doi: 10.1517/17425255.2015.1028917. PubMed PMID: 25802976.
  9. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics
  10. Jani M, Ambrus C, Magnan R, Jakab KT, Beery E, Zolnerciks JK, Krajcsi P., ARCH TOXICOL. 2014 88(6):1205-48. doi: 10.1007/s00204-014-1224-8. PubMed PMID: 24777822
  11. Drug-transporter interaction testing in drug discovery and development
  12. Péter Krajcsi, WORLD J PHARMACOL 2013 (1):35-46. Published online 2013 March 09 doi: 10.5497/WJP.v2.i1.35
  13. In vitro methods in drug transporter interaction assessment
  14. Márton Jani, Péter Krajcsi, In vitro methods in drug transporter interaction assessment, Drug Discovery Today: Technologies. 5 April 2014
  15. MDR-ABC Transporters - Biomarkers in Rheumatoid Arthritis
  16. Márki-Zay J, Tauberné Jakab K, Szerémy P, Krajcsi P. Clinical and Experimental Rheumatology 2013 May 27. [Epub ahead of print]
  17. Efflux transporters in the blood-brain interfaces - in vitro and in vivo methods and correlations.
  18. Krajcsi P, Jani M, Tóth B, Erdő F, Kis E, Beéry E, Sziráki I. EXPERT OPIN DRUG METAB TOXICOL. 2012 Apr;8(4):419-431.
  19. ABCC2/Abcc2 - a multispecific transporter with dominant excretory functions
  20. K. Jemnitz, K. Heredi-Szabo, L Vereczkey and P. Krajcsi
    Drug Metab Rev. 2010 Aug;42(3):402-36.
  21. Potentiation of MRP2/Mrp2-mediated Estradiol-17β-Glucuronide Transport by Drugs - A Concise Review
  22. K. Herédi Szabó, K. Jemnitz, E. Kis, E. Ioja, J. Jánossy, L. Vereczkey and P. Krajcsi
    Chem Biodivers. 2009 Nov;6(11):1970-4.
  23. Interaction of macrocyclic lactones with the multidrug transporters: the bases of the pharmacokinetics of lipid-like drugs
  24. A. Lespine, J. Dupuy, C. Borin, M. Alvinerie, C. Comera, T. Nagy, P. Krajcsi and S. Orlowski
    Curr Drug Metab. 2009 Mar;10(3):272-88.
  25. Ins and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays
  26. Csilla Hegedűs, Gergely Szakács, László Homolya, Tamás I. Orbán, Ágnes Telbisz, Márton Jani and Balázs Sarkadi
    Adv Drug Deliv Rev. 2009 Jan 31;61(1):47-56. Epub 2008 Dec 24.
  27. Utilization of membrane vesicle preparations to study drug-ABC transporter interactions
  28. Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi-Szabó K, Krajcsi P
    Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):721-32.
  29. The role of ABC transporters in drug resistance, metabolism and toxicity
  30. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B
    Curr Drug Deliv. 2004 Jan;1(1):27-42.

Role of transporters in drug ADME

  1. Membrane Assays to Characterize Interaction of Drugs with ABCB1
  2. Fekete Z, Rajnai Z, Nagy T, Jakab KT, Kurunczi A, Gemes K, Heredi-Szabo K, Fulop F, Toth GK, Czerwinski M, Loewen G, Krajcsi P. J MEMBR BIOL. 2015 248(6):967-77. doi: 10.1007/s00232-015-9804-y. PubMed PMID: 25926125.
  3. Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes
  4. Szabo M, Veres Z, Batai-Konczos A, Kekesi O, Kis E, Szabo K, Jemnitz K. TOXICOL IN VITRO. 2014 28(6):1136-43. doi: 10.1016/j.tiv.2014.05.016. PubMed PMID: 24909372.
  5. The use of microdialysis techniques in mice to study P-gp function at the blood-brain barrier
  6. Szolomajer-Csikos O, Beery E, Kosa L, Rajnai Z, Jani M, Hetenyi A, Jakab KT, Krajcsi P, Toth GK. Sziraki I, Erdo F, Trampus P, Sike M, Molnar PM, Rajnai Z, Molnar J, Wilhelm I, Fazakas C, Kis E, Krizbai I, Krajcsi P. J BIOMOL SCREEN. 2013 18(4):430-40. doi: 10.1177/1087057112468156. PubMed PMID: 23204072.
  7. Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs--specificity and structure activity correlations
  8. Szolomajer-Csikos O, Beery E, Kosa L, Rajnai Z, Jani M, Hetenyi A, Jakab KT, Krajcsi P, Toth GK. MED CHEM. 2013 9(4):494-509. doi: 10.2174/1573406411309040003. PubMed PMID: 22931494.
  9. Prediction of Therapy Response and Prognosis in Leukemias by Flow Cytometric MDR Assays
  10. Kappelmayer J, Hevessy Z, Apjok A, Jakab KT. EJIFCC. 2013 23(4):117-23. PubMed PMID: 27683427
  11. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats
  12. Erdo F, Gordon J, Wu JT, Sziraki I. BRAIN RES BULL. 2012 87(4-5):413-9. doi: 10.1016/j.brainresbull.2012.01.002. PubMed PMID: 22245027.
  13. The expressions of ABCC4 and ABCG2 xenobiotic transporters in human keratinocytes are proliferation-related
  14. Bebes A, Kis K, Nagy T, Kurunczi A, Polyanka H, Bata-Csorgo Z, Kemeny L, Dobozy A, Szell M. ARCH DERMATOL RES. 2012 304(1):57-63. doi: 10.1007/s00403-011-1174-4. PubMed PMID: 21922333.
  15. The vesicular transport assay: validated in vitro methods to study drug-mediated inhibition of canalicular efflux transporters ABCB11/BSEP and ABCC2/MRP2
  16. Heredi-Szabo K, Kis E, Krajcsi P. CURR PROTOC TOXICOL. 2012 Chapter 23:Unit 23 4. doi: 10.1002/0471140856.tx2304s54. PubMed PMID: 23169269
  17. Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity
  18. Heredi-Szabo K, Glavinas H, Kis E, Mehn D, Bathori G, Veres Z, Kobori L, von Richter O, Jemnitz K, Krajcsi P. DRUG METAB DISPOS. 2009 37(4):794-801. doi: 10.1124/dmd.108.023895. PubMed PMID: 19118132.
  19. Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2
  20. Jani M, Szabo P, Kis E, Molnar E, Glavinas H, Krajcsi P. BIOL PHARM BULL. 2009 32(3):497-9. doi: http://doi.org/10.1248/bpb.32.497 PubMed PMID: 19252303.
  21. [In vitro methods suitable for the prediction of drug and ABC transporter, especially ABCG2 interactions]
  22. Pal A, Kis E, Mehn D, Glavinas H, Nagy T, Meszaros P, Bathori G, Krajcsi P, Falkay G. ACTA PHARM HUNG. 2007 77(4):205-16. PubMed PMID: 18290540.
  23. Chlorothiazide is a substrate for the human uptake transporters OAT1 and OAT3.
  24. Juhász V, Beéry E, Nagy Z, Bui A, Molnár E, Zolnerciks JK, Magnan R, Jani M, Krajcsi P. J Pharm Sci. 2013 May;102(5):1683-7
  25. A P-gp vesicular transport inhibition assay - Optimization and validation for drug-drug interaction testing.
  26. Herédi-Szabó K, Palm JE, Andersson TB, Pál A, Méhn D, Beéry E, Jakab KT, Jani M, Krajcsi P. Eur J Pharm Sci. 2013 May 15
  27. Application of Receiver Operating Characteristic (ROC) Analysis to Refine the Prediction of Potential Digoxin Drug Interactions.
  28. Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung S, Heredi-Szabo K, Neuhof S, Palm JE, Balimane P, Zhang L, Jamei M, Hanna IH, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak A, Perloff E, Rajaraman G, Salphati L, Taur J, Weitz D, Wortelboer H, Xia C, Xiao G, Yamagata T, Lee CA. Drug Metab Dispos. 2013 Apr 25
  29. Interactions of bilastine, a new oral H1 antihistamine, with human transporter systems
  30. Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E, Gedey S, Jahic M, Bednarczyk D. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:8-17.
  31. ABCG2 modulates chlorothiazide permeability in vitro-characterization of its interactions.
  32. Erzsébet Beéry, Zsuzsanna Rajnai, Tibor Abonyi, Ildikó Makai, Száva Bánsághy, Franciska Erdő, István Sziráki, Emese Kis, Márton Jani, Gábor K Tóth, Peter Krajcsi Drug Metab Pharmacokinet. 2011 Nov 29.
  33. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells
  34. Walter Brand, Berend Oosterhuis, Peter Krajcsi, Denis Barron, Fabiola Dionisi, Peter J. van Bladeren, Ivonne M.C.M. Rietjens, Gary Williamson BIOPHARMACEUTICS & DRUG DISPOSITION 2011 Dec;32(9):530-5.
  35. Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy
  36. Attila Bebes, Tünde Nagy, Zsuzsanna Bata-Csörg, Lajos Kemény, Attila Dobozy, Márta Széll J Photochem Photobiol B. 2011 Nov 3;105(2):162-6. Epub 2011 Aug 23.
  37. Hepatic Metabolism and Disposition of Baicalein via the Coupling of Conjugation Enzymes and Transporters—In Vitro and In Vivo Evidences
  38. Li Zhang, Chenrui Li, Ge Lin, Peter Krajcsi, Zhong Zuo AAPS J. 2011 Sep;13(3):378-89. Epub 2011 May 24.
  39. Digoxin is not a Substrate for Organic Anion Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a Substrate for a Sodium Dependent Transporter Expressed in HEK293 Cells
  40. Taub ME, Mease KM, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa BP, Reyner EL, Jani M, Lee CA. Drug Metab Dispos. 2011 Aug 17.
  41. Quinidine as an ABCB1 Probe for Testing Drug Interactions at the Blood-Brain Barrier: An In Vitro In Vivo Correlation Study
  42. Sziráki I, Erdo F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, Makai I, Kis E, Herédi-Szabó K, Abonyi T, Krizbai I, Tóth GK, Krajcsi P. J Biomol Screen. 2011 Aug 10.
  43. Calcein assay: a high-throughput method to assess P-gp inhibition
  44. Glavinas H, von Richter O, Vojnits K, Mehn D, Wilhelm I, Nagy T, Janossy J, Krizbai I, Couraud P, Krajcsi P. Xenobiotica. 2011 Aug;41(8):712-9. Epub 2011 Jun 9.
  45. Comparison of 3 Assay Systems Using a Common Probe Substrate, Calcein AM, for Studying P-gp Using a Selected Set of Compounds
  46. Szerémy P, Pál A, Méhn D, Tóth B, Fülöp F, Krajcsi P, Herédi-Szabó K.
    J Biomol Screen. 2010 Nov 5.
  47. ATP-Binding Cassette B1 Transports Seliciclib (R-Roscovitine), a Cyclin-Dependent Kinase Inhibitor
  48. Zsuzsanna Rajnai, Dóra Méhn, Erzsébet Beéry, Alper Okyar, Márton Jani, Gábor K. Tóth, Ferenc Fülöp, Francis Lévi and Peter Krajcsi
    Drug Metab Dispos. 2010 Nov;38(11):2000-6. Epub 2010 Aug 10.
  49. MRP2-mediated E2-17βG transport potentiation: in vitro - in vivo correlation and species specificity
  50. K. Heredi-Szabo, H. Glavinas, E. Kis, D. Méhn, G. Báthori, Z. Veres, L. Kóbori, O. von Richter, K. Jemnitz and P. Krajcsi
    Drug Metab Dispos. 2009 Apr;37(4):794-801. Epub 2008 Dec 31.
  51. Kinetic characterization of sulfasalazine transport by human ABCG2 (BCRP)
  52. M. Jani, P. Szabó, E. Kis, É. Molnár, H. Glavinas, P. Krajcsi
    Biol Pharm Bull. 2009 Mar;32(3):497-9.
  53. Leflunomide and A771726, its metabolite are high affinity substrates of BCRP - implications for drug resistance
  54. Kis E, Nagy T, Jani M, Molnár E, Jánossy J, Ujhelly O, Német K, Herédi-Szabó K, Krajcsi P
    Ann Rheum Dis. 2009 Jul;68(7):1201-7. Epub 2008 Apr 8.
  55. A novel screening strategy to identify ABCB1 substrates and inhibitors
  56. O. von Richter, H. Glavinas, P. Krajcsi, S. Liehner, B. Siewert, K. Zech
    Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. Epub 2008 Aug 29.
  57. Characterization of 5(6)-carboxy-2,'7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4
  58. Heredi-Szabo K, Kis E, Molnar E, Gyorfi A, Krajcsi P
    J Biomol Screen. 2008 Apr;13(4):295-301. Epub 2008 Mar 18.
  59. In vitro methods suitable for the prediction of drug and ABC transporter, especially ABCG2 interactions
  60. Pál A, Kis E, Méhn D, Glavinas H, Nagy T, Mészáros P, Báthori G, Krajcsi P, Falkay G
    Acta Pharm Hung. 2007;77(4):205-16.
  61. Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes
  62. Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K.
    Hepatol Res. 2008 Mar;38(3):300-9. Epub 2007 Aug 29.
  63. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions
  64. Glavinas H, Kis E, Pál A, Kovács R, Jani M, Vági E, Molnár E, Bánsághi S, Kele Z, Janáki T, Báthori G, von Richter O, Koomen GJ, Krajcsi P
    Drug Metab Dispos. 2007 Sep;35(9):1533-42. Epub 2007 May 30.
  65. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2
  66. Pál A, Méhn D, Molnár E, Gedey S, Mészáros P, Nagy T, Glavinas H, Janáki T, von Richter O, Báthori G, Szente L, Krajcsi P
    J Pharmacol Exp Ther. 2007 Jun;321(3):1085-94. Epub 2007 Mar 8.
  67. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)
  68. Schmitt U, Abou El-Ela A, Guo LJ, Glavinas H, Krajcsi P, Baron JM, Tillmann C, Hiemke C, Langguth P, Härtter S
    J Neural Transm. 2006 Jul;113(7):787-801. Epub 2005 Oct 27.
  69. Comparative analysis of human multidrug resistance associated protein 2 (MRP2) and rat MRP2
  70. Krajcsi P, Glavinas H, Kis E, Kovács R, Pal A
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 25S1 (2005) S1–S226
  71. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells
  72. Özvegy Cs, Litman T, Szakács G, Nagy Z, Bates S, Váradi A, and Sarkadi B
    Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
  73. Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization
  74. Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Varadi A, Sarkadi B, Elkind NB
    Biochem Biophys Res Commun. 2004 Jul 30;320(3):860-7.

Role of transporters in drug toxicity

  1. BSEP inhibition – in vitro screens to assess cholestatic potential of drugs.
  2. Emese Kis, Enikő Ioja, Zsuzsa Rajnai, Márton Jani, Dóra Méhn, Krisztina Herédi-Szabó, Peter Krajcsi Toxicol In Vitro. 2011 Nov 18.
  3. Effect of membrane cholesterol on BSEP/Bsep activity - species specificity studies for substrates and inhibitors
  4. E. Kis, E. Ioja, T. Nagy, K. Herédi-Szabó and P. Krajcsi
    Drug Metab Dispos. 2009 Sep;37(9):1878-86. Epub 2009 Jun 11.
  5. Mouse Bsep ATPase assay: a nonradioactive tool for assessment of the cholestatic potential of drugs
  6. E. Kis, Z. Rajnai, E. Ioja, K. Herédi-Szabó, T. Nagy, D. Méhn and P. Krajcsi
    J Biomol Screen. 2009 Jan;14(1):10-5. Epub 2008 Nov 21.

Role of transporters in bioavailability of nutraceuticals and in risk assessement of environmental toxicants

  1. Interaction of hydroxycinnamic acids and their conjugates with organic anion transporters and ATP-binding cassette transporters
  2. Kalapos-Kovacs B, Magda B, Jani M, Fekete Z, Szabo PT, Antal I, Krajcsi P, Klebovich I. PHYTOTHER RES. 2015 29(12):1987-90. doi: 10.1002/ptr.5477. PubMed PMID: 26400418.
  3. Multiple ABC Transporters Efflux Baicalin
  4. Kalapos-Kovacs B, Magda B, Jani M, Fekete Z, Szabo PT, Antal I, Krajcsi P, Klebovich I. PHYTOTHER RES. 2015 29(12):1987-90. doi: 10.1002/ptr.5477. PubMed PMID: 26400418.
  5. Interaction of hydroxycinnamic acids and their conjugates with organic anion transporters and ATP-binding cassette transporters
  6. Chi C. Wong, Denis Barron, Caroline Orfila, Fabiola Dionisi, Peter Krajcsi and Gary Williamson MOL NUTR FOOD RES. 2011 Jul;55(7):979-88. doi: 10.1002/mnfr.201000652. Epub 2011 Apr 29.
  7. Ivermectin interacts with human ABCG2.
  8. M. Jani, I. Makai, E. Kis, P. Szabó, T. Nagy, P. Krajcsi and A. Lespine J PHARM SCI, J Pharm Sci. 2011 Jan;100(1):94-7
  9. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1
  10. Dreiseitel A, Oosterhuis B, Vukman KV, Schreier P, Oehme A, Locher S, Hajak G, Sand PG
    Br J Pharmacol. 2009 Dec;158(8):1942-50.
  11. Specific interactions of chloroacetanilide herbicides with human ABC transporter proteins
  12. Oosterhuis B, Vukman K, Vági E, Glavinas H, Jablonkai I, Krajcsi P
    Toxicology. 2008 Jun 3;248(1):45-51. Epub 2008 Mar 14.
  13. Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2)
  14. Williamson G, Aeberli I, Miguet L, Zhang Z, Sanchez MB, Crespy V, Barron D, Needs P, Kroon PA, Glavinas H, Krajcsi P, Grigorov M
    Drug Metab Dispos. 2007 Aug;35(8):1262-8. Epub 2007 May 3.
  15. Mechanistic study on the intestinal absorption and disposition of baicalein
  16. Zhang L, Lin G, Kovács B, Jani M, Krajcsi P, Zuo Z
    Eur J Pharm Sci. 2007 Jul;31(3-4):221-31. Epub 2007 Apr 9.
  17. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)
  18. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M
    Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27.

Miscellaneous

  1. mRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells
  2. Sike A, Nagy E, Vedelek B, Pusztai D, Szeremy P, Venetianer A, Boros IM. PLOS ONE. 2014 9(1):e84915.
  3. Characterisation of a GroEL Single-Ring Mutant that Supports Growth of Escherichia coli and Has GroES-Dependent ATPase Activity
  4. Kovács E, Sun Z, Liu H, Scott DJ, Karsisiotis AI, Clarke AR, Burston SG, Lund PA.
    J Mol Biol. 2010 Mar 12;396(5):1271-83. Epub 2009 Dec 16.
  5. Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties
  6. Fantin M, Quintieri L, Kúsz E, Kis E, Glavinas H, Floreani M, Padrini R, Duda E, Vizler C
    Eur J Pharmacol. 2006 Mar 27;535(1-3):301-9.

Book chapters

  1. Membrane transporters and transporter substrates as biomarkers for drug pharmacokinetics, pharmacodynamics, and toxicity/adverse events.
  2. In: Biomarkers in Toxicology. Ramesh Gupta, editors, Beáta Tóth , Péter Krajcsi and Rémi Magnan, Oxford: Academic Press, 2014, pp. 947-964. ISBN: 978-0-12-404630-6 Copyright © 2014 Elsevier Inc. Academic Press.
  3. Membrane and Dye Efflux Assays to Detect and Characterize the Interaction of Drugs with ABC Transporters
  4. Ioja E, Nagy Z, Juhász V, Jánossy J, Herédi-Szabó K, Krajcsi P.
    In: Solubility, Delivery and ADME problems of drugs and drug candidates
    Editors: Karoly Tihanyi and Monika Vastag
    2011, Bentham Scence Publishers Ltd. e-book, pp: 102-116 eBook ISBN: 978-1-60805-120-5
  5. ABC transporters in the blood-brain barrier - relevance in stroke therapy in Recent advances and new strategies in stroke research
  6. In: Recent advances and new strategies in stroke research (editors: Z Nagy, F Erdo)
    M. Bollók, J. Jánossy and P. Krajcsi
    2008, Transworld Research Network, Kerala, pp167-190
  7. Microdialysis techniques in stroke research: Experimental and clinical aspects
  8. In: Recent advances and new strategies in stroke research (editors: Z Nagy, F Erdo)
    F Erdő, F Andrási and I Sziráki
    2008, Transworld Research Network, Kerala, pp291-317

Relevant Scientific Publications

  1. Endicott, J.A. and Ling, V. Annu.Rev.Biochem., 1989, 58, 137-171.
  2. Higgins, C.F. Ann.Rev.Cell Biol., 1992, 8, 67-113.
  3. Gottesman, M.M. and Pastan, I. Annu.Rev.Biochem., 1993, 62, 385-427.
  4. Gottesman, M.M.; Fojo, T.; Bates, S.E. Nat. Rev. Cancer, 2002, 2 (1), 48-58.
  5. Klein, I.; Sarkadi, B.; Váradi, A. Biochim. Biophys. Acta, 1999, 1461 (2), 237-262.
  6. Ueda, K.; Taguchi, Y.; Morishima, M. Semin Cancer Biol., 1997, 8 (3), 151-159.
  7. Váradi, A.; Tusnády, G.E.; Sarkadi, B. In ABC Proteins From Bacteria to Man, Holland, I.B.; Cole, S.P.C.; Kuchler, K.; Higgins, C.F. Ed.; Elsevier Science, 2003, pp. 37-47.
  8. Karpowich, N.; Martsinkevich, O.; Millen, L.; Yuan, Y.R.; Dai, P.L.; MacVey, K.; Thomas, P.J.; Hunt, J.F. Structure, 2001, 9 (7), 571-86.
  9. Dean, M.; Rzhetsky, A.; Allikmets, R. Genome Res., 2001, 11 (7), 1156-1166.
  10. Linton, K.J.; Rosenberg, MF.; Kerr, I.D.; Higgins, C.F. In ABC Proteins From Bacteria to Man, Holland, I.B.; Cole, S.P.C.; Kuchler, K.; Higgins, C.F. Ed.; Elsevier Science, 2003, pp. 65-80
  11. Bates, S. In ABC Proteins From Bacteria to Man, Holland, I.B.; Cole, S.P.C.; Kuchler, K.; Higgins, C.F. Ed.; Elsevier Science, 2003, pp. 359-391.
  12. Arnould, I.; Schriml, L.; Prades, C.; Lachtermacher-Triunfol, M.; Schneider, T.; Maintoux, C. GeneScreen, 2001, 1, 157-164.
  13. Young, S.G. and Fielding, C.J. Nat. Genet, 1999, 22 (4), 316-318.
  14. Bodzioch, M.; Orso, E.; Klucken, J.; Langmann, T.; Bottcher, A.; Diederich, W.; Drobnik, W.; Barlage, S.; Buchler, C.; Porsch-Ozcurumez, M.; Kaminski, W.E.; Hahmann, H.W.; Oette, K.; Rothe, G.; Aslanidis, C.; Lackner, K.J.; Schmitz, G. Nat Genet. 1999, 22 (4), 347-51.
  15. Rust, S.; Rosier, M.; Funke, H.; Real, J.; Amoura, Z.; Piette, J.C.; Deleuze, J.F.; Brewer, H.B.; Duverger, N.; Denefle, P.; Assmann, G. Nat Genet., 1999, 22 (4), 352-5.
  16. Kaminski, W.E.; Orso, E.; Diederich, W.; Klucken, J.; Drobnik, W.; Schmitz, G. Biochem Biophys Res Commun., 2000, 273 (2), 532-8.
  17. Allikmets, R.; Singh, N.; Sun, H.; Shroyer, N.F.; Hutchinson, A.; Chidambaram, A.; Gerrard, B.; Baird, L.; Stauffer, D.; Peiffer, A.; Rattner, A.; Smallwood, P.; Li, Y.; Anderson, K.L.; Lewis, R.A.; Nathans, J.; Leppert, M.; Dean, M.; Lupski, J.R. Nat. Genet, 1997, 15 (3), 236-246.
  18. Allikmets, R. Am. J. Hum. Genet., 2000, 67 (4), 793-799.
  19. Juliano, R.L. and Ling, V.A. Biochim. Biophys. Acta, 1976, 455 (1), 152-162.
  20. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.; Willingham, M.C. Proc. Natl. Acad. Sci. U S A. 1987, 84 (21) 7735-7738.
  21. Abele, R.; Tampe, R. Biochim Biophys Acta. 1999 1461 (2), 405-19.
  22. van Helvoort, A.; Smith, A.J.; Sprong, H.; Fritzsche, I.; Schinkel, A.H.; Borst, P.; van Meer, G. Cell, 1996, 87 (3), 507-517.
  23. Deleuze, J.F.; Jacquemin, E.; Dubuisson, C.; Cresteil, D.; Dumont, M.; Erlinger, S.; Bernard, O.; Hadchouel, M. Hepatology, 1996, 23 (4) 904-8.
  24. de Vree, J.M.; Jacquemin, E.; Sturm, E.; Cresteil, D.; Bosma, P.J.; Aten, J.; Deleuze, J.F.; Desrochers, M.; Burdelski, M.; Bernard, O.; Oude Elferink, R.P.; Hadchouel, M. Proc Natl Acad Sci U S A., 1998, 6, 95 (1) 282-7.
  25. Strautnieks, S.S.; Bull, L.N.; Knisely, A.S.; Kocoshis, S.A.; Dahl, N.; Arnell, H.; Sokal, E.; Dahan, K.; Childs, S.; Ling, V.; Tanner, M.S.; Kagalwalla, A.F.; Nemeth, A.; Pawlowska, J.; Baker, A.; Mieli-Vergani, G.; Freimer, N.B.; Gardiner, R.M.; Thompson, R.J. Nat. Genet. 1998, 20 (3), 233-238.
  26. Zhang, F.; Zhang, W.; Liu, L.; Fisher, C.L.; Hui, D.; Childs, S.; Dorovini-Zis, K.; Ling, V. J Biol Chem. 2000, 275 (30), 23287-94.
  27. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A.M.; Deeley, R.G. Science, 1992, 258 (5088), 1650-1654.
  28. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. J. Natl. Cancer. Inst., 2000, 92 (16), 1295-1302.
  29. Deeley, R.G. and Cole, S.P.C. Semin.Cancer Biol., 1997, 8 (3), 193-204.
  30. Paulusma, C.C.; Bosma, P.J.; Zaman, G.J.; Bakker, C.T.; Otter, M.; Scheffer, G.L.; Scheper, R.J.; Borst, P.; Oude Elferink, R.P. Science, 1996, 271 (5252), 1126-1128.
  31. Cole, S.P.; Sparks, K.E.; Fraser, K.; Loe, D.W.; Grant, C.E.; Wilson, G.M.; Deeley, R.G. Cancer Res., 1994, 54 (22), 5902-10.
  32. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Toxicology. 2001, 167, (1), 3-23.
  33. Kartenbeck, J.; Leuschner, U.; Mayer, R.; Keppler, D. Hepatology, 1996, 23 (5),1061-6.
  34. Paulusma, C.C.; Kool, M.; Bosma, P.J.; Scheffer, G.L.; ter Borg, F.; Scheper, R.J.; Tytgat, G.N.; Borst, P.; Baas, F.; Oude Elferink, R.P. Hepatology, 1997, 25 (6), 1539-1542.
  35. Kool, M.; van der Linden, M.; de Haas, M.; Scheffer, G.L.; de Vree, J.M.; Smith, A.J.; Jansen, G.; Peters, G.J.; Ponne, N.; Scheper, R.J.; Elferink, R.P.; Baas, F.; Borst, P. Proc Natl Acad Sci USA, 1999, 96 (12), 6914-9.
  36. Konig, J.; Rost, D.; Cui, Y.; Keppler, D. Hepatology, 1999, 29 (4),1156-63
  37. Schuetz, J.D.; Connelly, M.C.; Sun, D.; Paibir, S.G.; Flynn, P.M.; Srinivas, R.V.; Kumar. A.; Fridland, A. Nat. Med., 1999, 5, (9) 1048-51.
  38. Rius, M.; Nies, A.T.; Hummel-Eisenbeiss, J.; Jedlitschky, G.; Keppler, D. Hepatology. 2003, 38 (2), 374-84.
  39. Wijnholds, J.; Mol, C.A.; van Deemter, L.; de Haas, M.; Scheffer, G.L.; Baas, F.; Beijnen, J.H.; Scheper, R.J.; Hatse, S.; De Clercq, E.; Balzarini, J.; Borst, P. Proc. Natl. Acad. Sci. U S A., 2000, 97, (13) 7476-81.
  40. Ilias, A.; Urban, Z.; Seidl, T.L.; Le Saux, O.; Sinko, E.; Boyd, C.D.; Sarkadi, B.; Varadi, A. J. Biol. Chem., 2002, 277 (19), 16860-7.
  41. Belinsky, M.G.; Chen, Z.S.; Shchaveleva, I.; Zeng, H.; Kruh, G.D. Cancer Research, 2002, 62 (21), 6172-7.
  42. Tammur, J.; Prades, C.; Arnould, I.; Rzhetsky, A.; Hutchinson, A.; Adachi, M.; Schuetz, J.D.; Swoboda, K.J.; Ptacek, L.J.; Rosier, M. Dean, M.; Allikmets, R. Gene. 2001, 273 (1):89-96.
  43. Rommens, J.M.; Iannuzzi, M.C.; Kerem, B.; Drumm, M.L.; Melmer, G.; Dean, M.; Rozmahel, R.; Cole, J.L.; Kennedy, D.; Hidaka, N.; et al. Science, 1989, 245 (4922), 1059-65.
  44. Hanrahan, J.W.; Gentzsch, M.; Riordan, J.R. In ABC Proteins From Bacteria to Man, Holland, I.B.; Cole, S.P.C.; Kuchler, K.; Higgins, C.F. Ed.; Elsevier Science, 2003, pp. 589-618.
  45. Aguilar-Bryan, L.; Nichols, C.G.; Wechsler, S.W.; Clement, J.P.; Boyd, A.E.; Gonzalez, G.; Herrera-Sosa, H.; Nguy, K.; Bryan, J.; Nelson, D.A. Science. 1995, 268 (5209), 423-6.
  46. Mosser, J.; Douar, A.M.; Sarde, C.O.; Kioschis, P.; Feil, R.; Moser, H.; Poustka, A.M.; Mandel, J.L.; Aubourg, P. Nature, 1993, 361 (6414), 726-730.
  47. Chen, H.; Rossier, C.; Lalioti, M.D.; Lynn, A.; Chakravarti, A.; Perrin, G.; Antonarakis, S.E. Am. J. Hum. Genet., 1996, 59, (1), 66-75.
  48. Klucken, J.; Buchler, C.; Orso, E.; Kaminski, W.E.; Porsch-Ozcurumez, M.; Liebisch, G.; Kapinsky, M.; Diederich, W.; Drobnik, W.; Dean, M.; Allikmets, R.; Schmitz, G. Proc Natl Acad Sci USA, 2000, 97, (2), 817-822.
  49. Berge, K.E.; Tian, H.; Graf, G.A.; Yu, L.; Grishin, N.V.; Schultz, J.; Kwiterovich, P.; Shan, B.; Barnes, R.; Hobbs, H.H. Science, 2000, 290 (5497),1771-1775.
  50. Shulenin, S.; Schriml, L.M.; Remaley, A.T.; Fojo, S.; Brewer, B.; Allikmets, R.; Dean, M. Cytogenet. Cell Genet., 2001, 92 (3-4), 204-208.
  51. Allikmets, R.; Schriml, L.M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. Cancer Res., 1998, 58 (23), 5337-5339.
  52. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. Proc Natl Acad Sci USA, 1998, 95 (26) 15665-15670.
  53. Miyake, H.; Tolcher, A.; Gleave, M.E. Cancer Res., 1999, 59 (16), 4030-4.
  54. Loo, T.W.; Clarke, D.M. J. Biol. Chem., 2001, 276 (40), 36877-36880.
  55. Higgins, C.F. and Gottesman, M.M. Trends. Biochem. Sci., 1992, 17 (1), 18-21.
  56. Qian, Y.M.; Qiu, W.; Gao, M.; Westlake, C.J.; Cole, S.P.; Deeley, R.G. J. Biol. Chem., 2001, 276 (42), 38636-38644.
  57. Homolya, L.; Varadi, A.; Sarkadi, B. Biofactors, 2003, 17 (1-4), 103-14.
  58. Ambudkar, S.V.; Dey, S.; Hrycyna, C.A.; Ramachandra, M.; Pastan, I.; Gottesman, M.M. Annu Rev Pharmacol Toxicol. 1999, 39, 361-98.
  59. Loo, T.W.; Clarke, D.M. J Biol Chem., 2001, 276 (18), 14972-9.
  60. Szabó, K.; Welker, E.; Bakos, Á.; Müller, M.; Roninson, I.; Varadi, A.; Sarkadi, B. J. Biol. Chem. 1998, 273 (17), 10132-10138.
  61. Hrycyna, C.A.; Ramachandra, M.; Ambudkar, S.V.; Ko, Y.H.; Pedersen, P.L.; Pastan, I.; Gottesman, M.M. J. Biol. Chem., 1998, 273 (27), 16631-16634.
  62. Hrycyna, C.A.; Airan, L.E.; Germann, U.A.; Ambudkar, S.V.; Pastan, I.; Gottesman, M.M. Biochemistry, 1998, 37 (39), 13660-13673.
  63. Sauna, Z.E.; Ambudkar, S.V. J. Biol. Chem., 2001, 276 (15), 11653-11661.
  64. Senior, A.E.; Gadsby, D.C. Semin Cancer Biol. 1997, 8 (3), 143-50.
  65. Ozvegy, C.; Varadi, A.; Sarkadi, B. J Biol Chem, 2002, 277 (50), 47980-90.
  66. Rao, V.V.; Dahlheimer, J.L.; Bardgett, M.E.; Snyder, A.Z.; Finch, R.A.; Sartorelli, A.C.; Piwnica-Worms, D. Proc. Natl. Acad. Sci., 1999, 96 (7), 3900-3905.
  67. Bart, J.; Groen, H.J.; Hendrikse, N.H.; van der Graaf, W.T.; Vaalburg, W.; de Vries, E.G. Cancer Treat. Rev., 2000, 26 (6), 449-462.
  68. Bates, S.E.; Robey, R.; Miyake, K.; Rao, K.; Ross, D.D.; Litman, T. J. Bioenerg. Biomembr., 2001, 33 (6) 503-511.
  69. Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M.; Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. Nat. Med., 2001, 7 (9), 1028-1034.
  70. Kipp, H.; Arias, I.M. Semin. Liver Dis., 2000, 20 (3), 339-351.
  71. Jonker, J.W.; Smit, J.W.; Brinkhuis, R.F.; Maliepaard, M.; Beijnen, J.H.; Schellens, J.H.; Schinkel, A.H. J. Natl. Cancer Inst., 2000, 92 (20), 1651-1656.
  72. Ozvegy, C.; Litman, T.; Szakacs, G.; Nagy, Z.; Bates, S.; Varadi, A.; Sarkadi, B. Biochem Biophys Res Commun., 2001, 285 (1), 111-7.
  73. Bodo, A., Bakos, E., Szeri, F., Varadi, A., Sarkadi, B.; J Biol Chem. 2003, 278, (26), 23529-37
  74. Zelcer, N.; Huisman, M.T.; Reid, G.; Wielinga, P.; Breedveld, P.; Kuil, A.; Knipscheer, P.; Schellens, J.H.; Schinkel, A.H.; Borst, P. J Biol Chem. 2003, 278, (26), 23538-44. Epub 2003 Apr 17
  75. Goldstein, L.J.; Pastan, I.; Gottesman, M.M. Crit Rev Oncol Hematol. 1992, 12 (3), 243-53.
  76. Borst, P.; Elferink, R.O. Annu Rev Biochem., 2002, 71, 537-92. Epub 2001 Nov 09.
  77. Borst, P.; Kool, M.; Evers, R. Semin Cancer Biol., 1997, 8 (3) 205-13.
  78. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. Biochim Biophys Acta., 1999, 1461 (2) 347-57.
  79. Hipfner, D.R.; Deeley, R.G.; Cole, S.P. Biochim Biophys Acta. 1999, 1461 (2), 359-76.
  80. Hirohashi, T.; Suzuki, H.; Sugiyama, Y. J Biol Chem., 1999, 274 (21), 15181-5.
  81. Litman, T.; Druley, T.E.; Stein, W.D.; Bates, S.E. Cell Mol Life Sci, 2001, 58 (7), 931-59.
  82. Lecureur, V.; Courtois, A.; Payen, L.; Verhnet, L.; Guillouzo, A.; Fardel, O. Toxicology., 2000, 153 (1-3), 203-19.
  83. Smith, A.J.; van Helvoort, A.; van Meer, G.; Szabo, K.; Welker, E.; Szakacs, G,; Varadi, A.; Sarkadi, B.; Borst, P. J Biol Chem., 2000, 275 (31), 23530-9.
  84. List, A.F.; Kopecky, K.J.; Willman, C.L.; Head, D.R.; Persons, D.L.; Slovak, M.L.; Dorr, R.; Karanes, C.; Hynes, H.E.; Doroshow, J.H.; Shurafa, M.; Appelbaum, F.R. Blood, 2001, 98 (12), 3212-20.
  85. Krishna, R.; Mayer, L.D. Eur J Pharm Sci., 2000, 11 (4), 265-83.
  86. Sharom, F.J.; Yu, X.; Lu, P.; Liu, R.; Chu, J.W.; Szabo, K.; Muller, M.; Hose, C.D.; Monks, A.; Varadi, A.; Seprodi, J.; Sarkadi, B. Biochem Pharmacol. 1999, 58 (4), 571-86.
  87. Oram, J.F.; Lawn, R.M. J Lipid Res., 2001, 42 (8), 1173-9.
  88. Srivastava, N. Mol Cell Biochem., 2002, 237 (1-2), 155-64.
  89. Schmitz, G.; Langmann, T. Curr Opin Lipidol., 2001, 12 (2), 129-40.
  90. Oram, J.F. Trends Mol Med., 2002, 8 (4), 168-73.
  91. Oram, J.F. Curr Opin Lipidol., 2002, 13 (4), 373-81.
  92. Schmitz, G.; Kaminski, W.E.; Front Biosci., 2001, 6, D505-14.
  93. Santamarina-Fojo, S.; Remaley, A.T.; Neufeld, E.B.; Brewer, H.B. Jr. J Lipid Res., 2001, 42 (9), 1339-45.
  94. Graf, G.A.; Li, W.P.; Gerard, R.D.; Gelissen, I.; White, A.; Cohen, J.C.; Hobbs, H.H. J Clin Invest., 2002, 110 (5), 659-69.
  95. Bunting, K.D.; Zhou, S.; Lu, T.; Sorrentino, B.P. Blood., 2000, 96 (3), 902-9.
  96. Hafkemeyer, P.; Licht, T.; Pastan, I.; Gottesman, M.M. Hum Gene Ther., 2000, 11, (4), 555-65.
  97. Schiedlmeier, B.; Schilz, A.J.; Kuhlcke, K.; Laufs, S.; Baum, C.; Zeller, W.J.; Eckert, H.G.; Fruehauf, S. Hum Gene Ther., 2002, 13 (2), 233-42.
  98. Sellers, S.E.; Tisdale, J.F.; Agricola, B.A.; Metzger, M.E.; Donahue, R.E.; Dunbar, C.E.; Sorrentino, B.P. Blood., 2001, 97 (6), 1888-91.
  99. Smeets, M.E.; Raymakers, R.A.; Vierwinden, G.; Pennings, A.H.; Wessels, H.; de Witte, T. Blood., 1999, 94 (7), 2414-23.
  100. Ross, D.D.; Yang, W.; Abruzzo, L.V.; Dalton, W.S.; Schneider, E.; Lage, H.; Dietel, M.; Greenberger, L.; Cole, S.P.; Doyle, L.A. J Natl Cancer Inst. 1999, 91 (5), 429-33.
  101. Litman, T.; Brangi, M.; Hudson, E.; Fetsch, P.; Abati, A.; Ross, D.D.; Miyake, K.; Resau, J.H.; Bates, S.E. J Cell Sci., 2000, 3 ( Pt 11), 2011-21.
  102. Bunting, K.D. Stem Cells., 2002, 20 (1), 11-20.
  103. Kim, M.; Turnquist, H.; Jackson, J.; Sgagias, M.; Yan, Y.; Gong, M.; Dean, M.; Sharp, J.G.; Cowan, K. Clin Cancer Res, 2002, 8 (1), 22-28.
  104. Honjo, Y.; Hrycyna, C.A.; Yan, Q.W.; Medina-Perez, W.Y.; Robey, R.W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S.E. Cancer Res., 2001, 61 (18), 6635-9.
  105. Aungst, B.J.; J Pharm Sci, 1993, 82 (10), 979-987.
  106. Kruijtzer, C.M.; Beijnen, J.H.; Schellens, J.H. The Oncologist, 2002, 7 (6), 516-30.
  107. Taipalensuu, J.; Tornblom, H.; Lindberg, G.; Einarsson, C.; Sjoqvist, F.; Melhus, H.; Garberg, P.; Sjostrom, B.; Lundgren, B.; Artursson, P. J Pharm Exp Ther, 2001, 299 (1), 164.
  108. Sparreboom, A.; van Asperen, J.; Mayer, U.; Schinkel, A.H.; Smit, J.W.; Meijer, D.K.; Borst, P.; Nooijen, W.J.; Beijnen, J.H.; van Tellingen, O. Proc Nat Acad Sci USA, 1997, 94 (5), 2031-5.
  109. van Asperen, J.; van Tellingen, O.; Sparreboom, A.; Schinkel, A.H.; Borst, P.; Nooijen, W.J.; Beijnen, J.H. Br J Cancer, 1997, 76 (9), 1181-3.
  110. Dietrich, C.G.; de Waart, D.R.; Ottenhoff, R.; Schoots, I.G.; Elferink, R.P. Mol Pharmacol, 2001, 59 (5), 974-80.
  111. Lin H.J. and Yamazaki M, Clin Pharmacokinet, 2003, 42, (1), 59-98
  112. Sugiyama et al. (1999) J Cont Release 62: 179-186
  113. Mahar Doan, K.M.; Humphreys, J.E.; Webster, L.O.; Wring, S.A.; Shampine, L.J.; Serabjit-Singh, C.J.; Adkison, K.K.; Polli, J.W. J Pharm Exp Therapeutics, 2002, 303 (3), 1029-1037.
  114. Ghersi-Egea, J.F.; Strazielle, N. Microsc Res Techn, 2001, 52 (1), 83-88.
  115. Wijnholds, J.; deLange, E.C.; Scheffer, G.L.; van den Berg, D.J.; Mol, C.A.; van der Valk, M.; Schinkel, A.H.; Scheper, R.J.; Breimer, D.D.; Borst, P. J Clin Invest, 2000, 105 (3), 279-85.
  116. Potschka, H.; Fedrowitz, M.; Loscher, W. J Pharmacol Exp Ther, 2003, 306 (1), 124-31.
  117. Fricker, G.; Nobmann, S.; Miller, D.S. Br J Pharmacol, 2002, 135 (5), 1308-14.
  118. Cooray, H.C.; Blackmore, C.G.; Maskell, L.; Barrand, M.A. Neuroreport, 2002, 13 (16), 2059-63.
  119. Lankas, G.R.; Wise, L.D.; Cartwright, M.E.; Pippert, T.; Umbenhauer, D.R. Reprod Toxicol, 1998, 12 (4), 457-463.
  120. St-Pierre, M.V.; Serrano, M.A.; Macias, R.I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P.J.; Marin, J.J. Am J Physiol Regul Integr Comp Physiol., 2000, 279 (4), R1495-503.
  121. von Richter, O.; Greiner, B.; Fromm, M.F.; Fraser, R.; Omari, T.; Barclay, M.L.; Dent, J.; Somogyi, A.A.; Eichelbaum, M. Clin Pharmacol Ther, 2001, 70 (3), 217-227.
  122. Mayer, U.; Wagenaar, E.; Dorobek, B.; Beijnen, J.H.; Borst, P.; Schinkel, A.H. J Clin Invest, 1997, 100 (10), 2430-2436.
  123. Hochman, J.H.; Chiba, M.; Yamazaki, M.; Tang, C.; Lin, J.H. J Pharmacol Exp Ther, 2001, 298 (1), 323-330.
  124. Lin, J.H.; Chiba, M.; Chen, I.W.; Nishime, J.A.; deLuna, F.A.; Yamazaki, M.; Lin, Y.J. Drug Metab Dispos, 1999, 27 (10), 1187-1193.
  125. Kawahara, M.; Sakata, A.; Miyashita, T.; Tamai, I.; Tsuji, A. J Pharm Sci, 1999, 88 (12), 1281-1287.
  126. van Asperen, J.; van Tellingen, O.; Tijssen, F.; Schinkel, A.H.; Beijnen, J.H. Br J Cancer, 1999, 79 (1), 108-13.
  127. Smit, J.W.; Schinkel, A.H.; Weert, B.; Meijer, D.K. Br J Pharmacol, 1998, 124 (2), 416-424.
  128. Stieger, B.; Fattinger, K.; Madon, J.; Kullak-Ublick, G.A.; Meier, P.J. Gastroenterology, 2000, 118 (2), 422-430.
  129. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H.P.; von Richter, O.; Zundler, J.; Kroemer, H.K J Clin Invest, 1999, 104 (2), 147-153.
  130. Hamman, M.A.; Bruce, M.A.; Haehner-Daniels, B.D.; Hall, S.D. Clin Pharmacol Ther, 2001, 69 (3), 114-121.
  131. Deferme, S.; Van Gelder, J.; Augustijns, P. J Pharm Pharmacol, 2002, 54 (9), 1213-1219.
  132. Marques-Santos, L.F.; Bernardo, R.R.; de Paula, E.F.; Rumjanek, V.M. Pharmacol Toxicol, 1999, 84 (3), 125-129.
  133. Schinkel, A.H.; Smit, J.J.; van Tellingen, O.; Beijnen, J.H.; Wagenaar, E.; van Deemter, L.; Mol, C.A.; van der Valk, M.A.; Robanus-Maandag, E.C.; te Riele, H.P. et al. Cell, 1994, 77 (4), 491-502.
  134. Kala, S.V.; Neely, M.W.; Kala, G.; Prater, C.I.; Atwood, D.W.; Rice, J.S.; Lieberman, M.W. J Biol Chem, 2000, 275 (43), 33404-33408.
  135. Scheffer, G.L.; Kool, M.; de Haas, M.; de Vree, J.M.; Pijnenborg, A.C.; Bosman, D.K.; Elferink, R.P.; van der Valk, P.; Borst, P.; Scheper, R.J. Lab Invest, 2002, 82 (2), 193-201.
  136. Hirohashi, T.; Suzuki, H.; Ito, K.; Ogawa, K.; Kume, K.; Shimizu, T.; Sugiyama, Y. Mol Pharmacol, 1998, 53 (6), 1068-1075.
  137. Fattinger, K.; Funk, C.; Pantze, M.; Weber, C.; Reichen, J.; Stieger, B.; Meier, P.J. Clin Pharmacol Ther, 2001, 69 (4), 223-231.
  138. Funk, C.; Ponelle, C.; Scheuermann, G.; Pantze, M. Mol Pharmacol, 2001, 59 (3), 627-635.
  139. Zhang, Y.; Bachmeier, C.; Miller, D.W. Adv Drug Deliv Rev, 2003, 55 (1), 31-51.
  140. Zeng, H.; Liu, G.; Rea, P.A.; Kruh, G.D.; Cancer Res. 2000, 60 (17), 4779-84.
  141. Sarkadi, B.; Price, E.M.; Boucher, R.C.; Germann, U.A.; Scarborough, G.A. J Biol Chem. 1992, 267 (7), 4854-8.
  142. Breuninger, L.M.; Paul, S.; Gaughan, K.; Miki, T.; Chan, A.; Aaronson, S.A.; Kruh, G.D. Cancer Res, 1995, 55 (22), 5342-7.
  143. Reid, G.; Wielinga, P.; Zelcer, N.; De Haas, M.; Van Deemter, L.; Wijnholds, J.; Balzarini, J.; Borst, P. Mol Pharmacol. 2003, 63 (5), 1094-103.
  144. Feller, N.; Kuiper, C.M.; Lankelma, J.; Ruhdal, J.K.; Scheper, R.J.; Pinedo, H.M.; Broxterman, H.J. Br J Cancer, 1995, 72 (3), 543-9. Erratum in: Br J Cancer 1996, 74, 2042.
  145. Weaver, J.L.; Pine, P.S.; Aszalos, A.; Schoenlein, P.V.; Currier, S.J.; Padmanabhan, R.; Gottesman, M.M. Exp Cell Res 1991, 196 (2), 323-329.
  146. Lee, J.S.; Paull, K.; Alvarez, M.; Hose, C.; Monks, A.; Grever, M.; Fojo, A.T.; Bates, S.E. Mol Pharmacol 1994, 46 (4), 627-638.
  147. Chaudhury, P.M. and Roninson, I.B. Cell, 1991, 66 (1), 85-94.
  148. Homolya, L.; Hollo, Z.; Germann, U.A.; Pastan, I.; Gottesman, M.M.; Sarkadi, B. J Biol Chem. 1993, 268 (29), 21493-6.
  149. Haugland, R.P. and Larison, K.D. In Handbook of Fluorescent Probes and Research Chemicals, Molecular Probes, Eugene, OR, 1992-94, pp 163, 172-173
  150. Hollo, Z.; Homolya, L.; Hegedus, T.; Sarkadi, B. FEBS Lett 1996, 383 (1-2), 99-104.
  151. Karaszi, E.; Jakab, K.; Homolya, L.; Szakacs, G.; Hollo, Z.; Telek, B.; Kiss, A.; Rejto, L.; Nahajevszky, S.; Sarkadi, B.; Kappelmayer, J. Br J Hematol 2001, 112 (2), 308-314.
  152. Gaillard, P.J.; van der Sandt, I.C.; Voorwinden, L.H.; Vu, D.; Nielsen, J.L.; de Boer, A.G.; Breimer, D.D. Pharm Res, 2000, 17 (10), 1198-1205.
  153. Adachi, Y.; Suzuki, H.; Sugiyama, Y. Pharm. Res, 2001, 18 (12), 1660-1668.
  154. Sukhai, M. and Piquette-Miller, M. J Pharm Pharmaceut Sci, 2000<, 3 (2), 268-280.
  155. Mechetner, E.B.; Roninson, I.B. Proc Nat Acad Sci USA, 1992, 89 (13), 5824-8.
  156. Mechetner, E.B.; Schott, B.; Morse, B.S.; Stein, W.D.; Druley, T.; Davis, K.A.; Tsuruo, T.; Roninson, I.B. Proc Nat Acad Sci USA, 1997, 94 (24), 12908-13.
  157. Nagy, H.; Goda, K.; Arceci, R.; Cianfriglia, M.; Mechetner, E.; Szabo, G. Jr. Eur J Biochem, 2001, 268 (8), 2416-20.
  158. Tabas, L.B. and Dantzig, A.H. Anal Biochem, 2002, 310 (1), 61-66.
  159. Bakos Á., Evers R., Sinkó E., Váradi A., Borst P., Sarkadi B.: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol, 2000; 57:760-768
  160. Holló Zs., Homolya L., Davis C.W., Sarkadi B.: Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1994; 1191: 384-388
  161. Homolya L., Holló Z., Müller M., Mechetner E.B., Sarkadi B.: A new method for quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer 1996; 73: 849-855
  162. Sarkadi B., Muller M., Homolya L. Hollo Zs., Seprodi J., Germann U.A., Gottesman M.M., Price E.M., Boucher R.C.: Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J. 1994, 8: 766-770
  163. Szabo K., Welker E., Bakos E., Muller M., Roninson I., Varadi A., Sarkadi B.: Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. Cooperation of the nucleotide binding domains. J Biol Chem 1998; 273: 10132-10138
  164. Taguchi Y., Yoshida A., Takada Y., Komano T., Ueda K.: Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett. 1997; 401: 11-14
  165. BodÁ A., Bakos Á., Szeri F., Váradi A., Sarkadi B.: The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicology Letters Toxicol Lett. 2003 Apr 11;140-141:133-43.
  166. Madon J, Eckhardt U, Gerloff T, Stieger B, Meier PJ.: Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. FEBS Lett. 1997 Apr 7;406(1-2):75-8.
  167. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ.: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998 Apr 17;273(16):10046-50
  168. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ.: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58.
  169. NoÁ J, Stieger B, Meier PJ.: Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology. 2002 Nov;123(5):1659-66.
  170. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R.: Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001 Oct 5;167(1):83-98.
  171. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ.: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30.
  172. Kullak-Ublick GA, Stieger B, Meier PJ.: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2004 Jan;126(1):322-42
  173. Faber KN, Muller M, Jansen PL.: Drug transport proteins in the liver. Adv Drug Deliv Rev. 2003 Jan 21;55(1):107-24.
  174. Kaplowitz N, DeLeve LD, Drug-induced liver disease. Eds Part II: Jansen Peter LM, Müller M.: The role of membrane transport in drug-induced hepatotoxicity and cholestasis; Marcel Dekker. 2003
  175. Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Varadi A, Sarkadi B, Elkind NB.: Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization. Biochem Biophys Res Commun. 2004 Jul 30;320(3):860-7.
  176. Van Aubel RA, Smeets PH, van den Heuvel JJ, and Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288: F327-F333, 2004
  177. Van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol. 2005 Feb;288(2):F327-33. Epub 2004 Sep 28. PMID: 15454390 [PubMed - indexed for MEDLINE]
  178. Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors. 2003;17(1-4):103-14. Review. PMID: 12897433 [PubMed - indexed for MEDLINE]
  179. Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13: 595-603, 2002